Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

奥拉帕尼 帕博西利布 癌症研究 三阴性乳腺癌 PARP抑制剂 乳腺癌 医学 合成致死 癌症 内科学 生物 DNA修复 聚ADP核糖聚合酶 转移性乳腺癌 遗传学 聚合酶 基因
作者
Xiu-Zhi Zhu,Li Chen,Binhao Huang,Xiaoguang Li,Yang Liu,Xin Hu,Yi‐Zhou Jiang,Zhimin Shao,Zhonghua Wang
出处
期刊:Journal of Experimental & Clinical Cancer Research [BioMed Central]
卷期号:40 (1): 122-122 被引量:94
标识
DOI:10.1186/s13046-021-01930-w
摘要

Abstract Background PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib in TNBC can be improved by combination with the CDK4/6 inhibitor (CDK4/6i) palbociclib. Methods We screened primary olaparib-sensitive and olaparib-resistant cell lines from existing BRCA mut /TNBC cell lines and generated cells with acquired olaparib resistance by gradually increasing the concentration. The effects of the PARPi olaparib and the CDK4/6i palbociclib on BRCA mut /TNBC cell lines were examined in both sensitive and resistant cells in vitro and in vivo. Pathway and gene alterations were assessed mechanistically and pharmacologically. Results We demonstrated for the first time that the combination of olaparib and palbociclib has synergistic effects against BRCA mut /TNBC both in vitro and in vivo. In olaparib-sensitive MDA-MB-436 cells, the single agent olaparib significantly inhibited cell viability and affected cell growth due to severe DNA damage. In olaparib-resistant HCC1937 and SUM149 cells, single-agent olaparib was ineffective due to potential homologous recombination (HR) repair, and the combination of olaparib and palbociclib greatly inhibited HR during the G2 phase, increased DNA damage and inhibited tumour growth. Inadequate DNA damage caused by olaparib activated the Wnt signalling pathway and upregulated MYC. Further experiments indicated that the overexpression of β-catenin, especially its hyperphosphorylation at the Ser675 site, activated the Wnt signalling pathway and mediated olaparib resistance, which could be strongly inhibited by combined treatment with palbociclib. Conclusions Our data provide a rationale for clinical evaluation of the therapeutic synergy of the PARPi olaparib and CDK4/6i palbociclib in BRCA mut /TNBCs with high Wnt signalling activation and high MYC expression that do not respond to PARPi monotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
冷傲的白柏完成签到,获得积分10
2秒前
霁月发布了新的文献求助10
3秒前
3秒前
自由的雪一完成签到,获得积分10
3秒前
4秒前
Olive发布了新的文献求助10
4秒前
完美世界的应助被六月雪采纳,获得10
5秒前
5秒前
霁月发布了新的文献求助10
6秒前
6秒前
霁月发布了新的文献求助10
6秒前
霁月发布了新的文献求助10
6秒前
霁月发布了新的文献求助10
6秒前
ZZKKZZ发布了新的文献求助10
6秒前
7秒前
7秒前
8秒前
9秒前
10秒前
所所的应助被dieeee采纳,获得10
10秒前
科研通AI2S的应助被清秀千兰采纳,获得10
11秒前
11秒前
小SCI发布了新的文献求助10
11秒前
11秒前
12秒前
uu发布了新的文献求助10
12秒前
12秒前
12秒前
噗噗发布了新的文献求助10
12秒前
万能图书馆的应助被Steven采纳,获得30
14秒前
14秒前
Ashore发布了新的文献求助10
14秒前
辛勤采柳发布了新的文献求助10
15秒前
15秒前
16秒前
16秒前
null的应助被科研通管家采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541